NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$25.00 +0.06 (+0.24 %)
(As of 05/25/2018 08:00 AM ET)
Previous Close$24.94
Today's Range$24.70 - $25.65
52-Week Range$16.98 - $37.00
Volume134,000 shs
Average Volume354,096 shs
Market Capitalization$703.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals logoDova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Debt-to-Equity RatioN/A
Current Ratio35.32
Quick Ratio35.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.44 per share
Price / Book5.63

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-29,950,000.00
Net MarginsN/A
Return on Equity-61.19%
Return on Assets-43.40%

Miscellaneous

Employees33
Outstanding Shares28,190,000

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals (NASDAQ:DOVA) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.05. View Dova Pharmaceuticals' Earnings History.

What price target have analysts set for DOVA?

4 brokerages have issued 1-year target prices for Dova Pharmaceuticals' stock. Their predictions range from $29.00 to $35.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $32.25 in the next twelve months. View Analyst Ratings for Dova Pharmaceuticals.

Who are some of Dova Pharmaceuticals' key competitors?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Mr. Alexander C. Sapir, Pres, CEO & Director (Age 51)
  • Dr. Lee F. Allen, Chief Medical Officer (Age 66)
  • Mr. Mark W. Hahn, Chief Financial Officer (Age 55)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 40)

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Has Dova Pharmaceuticals been receiving favorable news coverage?

Media headlines about DOVA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the company an impact score of 45.89 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Dova Pharmaceuticals' major shareholders?

Dova Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.30%), Nexthera Capital LP (2.02%), Wells Fargo & Company MN (1.20%), Pier Capital LLC (0.77%), GW&K Investment Management LLC (0.51%) and venBio Select Advisor LLC (0.44%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

Which institutional investors are buying Dova Pharmaceuticals stock?

DOVA stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, venBio Select Advisor LLC, Nexthera Capital LP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., Pier Capital LLC and Wells Fargo & Company MN. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $25.00.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $703.09 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (DOVA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dova Pharmaceuticals (NASDAQ:DOVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Dova Pharmaceuticals in the last 12 months. Their average twelve-month price target is $32.25, suggesting that the stock has a possible upside of 29.00%. The high price target for DOVA is $35.00 and the low price target for DOVA is $29.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.25$32.25$33.3333$32.3333
Price Target Upside: 29.00% upside7.57% upside16.43% upside44.02% upside

Dova Pharmaceuticals (NASDAQ:DOVA) Consensus Price Target History

Price Target History for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ:DOVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018Ladenburg ThalmannInitiated CoverageBuyHighView Rating Details
3/23/2018Evercore ISIInitiated CoverageIn ➝ line$29.00HighView Rating Details
11/28/2017Jefferies GroupBoost Price TargetBuy$33.00HighView Rating Details
9/26/2017Leerink SwannUpgradeMarket Perform ➝ Outperform$32.00HighView Rating Details
7/24/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$35.00HighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dova Pharmaceuticals (NASDAQ:DOVA) Earnings History and Estimates Chart

Earnings by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ:DOVA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.52)($0.42)($0.47)
Q2 20182($0.68)($0.54)($0.61)
Q3 20182($0.57)($0.49)($0.53)
Q4 20182($0.53)($0.32)($0.43)

Dova Pharmaceuticals (NASDAQ DOVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.4670)($0.52)ViewN/AView Earnings Details
2/15/2018Q4 2017($0.36)($0.36)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.30)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.24)($0.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dova Pharmaceuticals (NASDAQ:DOVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 55.50%
Institutional Ownership Percentage: 35.93%
Insider Trading History for Dova Pharmaceuticals (NASDAQ:DOVA)
Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Paul B ManningDirectorBuy25,870$22.30$576,901.00View SEC Filing  
8/15/2017Steven M GoldmanDirectorBuy20,169$22.23$448,356.8781,158View SEC Filing  
7/5/2017Alex SapirCEOBuy20,100$17.00$341,700.0020,100View SEC Filing  
7/5/2017Kevin LaliberteVPBuy6,200$17.00$105,400.006,200View SEC Filing  
7/5/2017Lee F Md Phd AllenInsiderBuy3,500$17.00$59,500.003,500View SEC Filing  
7/5/2017Steven M GoldmanDirectorBuy72,000$17.94$1,291,680.0042,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dova Pharmaceuticals (NASDAQ DOVA) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Forecast for Dova Pharmaceuticals (DOVA) Issued By Leerink SwannQ2 2018 Earnings Forecast for Dova Pharmaceuticals (DOVA) Issued By Leerink Swann
www.americanbankingnews.com - May 24 at 7:56 AM
Dova Pharmaceuticals Tumbles On FDA Approval, Golden Opportunity EmergesDova Pharmaceuticals Tumbles On FDA Approval, Golden Opportunity Emerges
seekingalpha.com - May 22 at 9:22 AM
Dova Pharmaceuticals (DOVA) Confirms FDA Approval of DOPTELETDova Pharmaceuticals (DOVA) Confirms FDA Approval of DOPTELET
www.streetinsider.com - May 21 at 4:22 PM
FDA approves Dovas drugFDA approves Dova's drug
www.bizjournals.com - May 21 at 4:22 PM
Dova Pharmas blood disorder drug gets FDA approvalDova Pharma's blood disorder drug gets FDA approval
finance.yahoo.com - May 21 at 4:22 PM
Dova Receives FDA Nod For Bleeding Disorder Treatment; Rival Drug Awaits ClearanceDova Receives FDA Nod For Bleeding Disorder Treatment; Rival Drug Awaits Clearance
finance.yahoo.com - May 21 at 4:22 PM
Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)
finance.yahoo.com - May 21 at 4:22 PM
FDA approves Dova's drugFDA approves Dova's drug
finance.yahoo.com - May 21 at 4:22 PM
Dova Pharmaceuticals (DOVA) Upgraded at BidaskClubDova Pharmaceuticals (DOVA) Upgraded at BidaskClub
www.americanbankingnews.com - May 18 at 5:13 PM
Dova Pharmaceuticals (DOVA) Raised to "Hold" at Zacks Investment ResearchDova Pharmaceuticals (DOVA) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 14 at 10:54 PM
Brokers Offer Predictions for Dova Pharmaceuticals Q2 2018 Earnings (DOVA)Brokers Offer Predictions for Dova Pharmaceuticals' Q2 2018 Earnings (DOVA)
www.americanbankingnews.com - May 14 at 2:33 AM
Jefferies Group Weighs in on Dova Pharmaceuticals Q2 2018 Earnings (DOVA)Jefferies Group Weighs in on Dova Pharmaceuticals' Q2 2018 Earnings (DOVA)
www.americanbankingnews.com - May 14 at 2:33 AM
Dova Pharmaceuticals (DOVA) CEO Alex Sapir on Q1 2018 Results - Earnings Call TranscriptDova Pharmaceuticals' (DOVA) CEO Alex Sapir on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:18 AM
Dova Pharmaceuticals (DOVA) Receives Consensus Rating of "Hold" from AnalystsDova Pharmaceuticals (DOVA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 1:33 AM
Dova Pharmaceuticals (DOVA) Posts  Earnings Results, Misses Expectations By $0.05 EPSDova Pharmaceuticals (DOVA) Posts Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 11 at 6:16 PM
Dova preps for FDA decision, launch of CLD drugDova preps for FDA decision, launch of CLD drug
finance.yahoo.com - May 10 at 4:29 PM
Dova Pharmaceuticals: 1Q Earnings SnapshotDova Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:48 AM
Dova Pharmaceuticals (DOVA) Downgraded to Strong Sell at BidaskClubDova Pharmaceuticals (DOVA) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - May 9 at 6:39 PM
BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $0.52BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $0.52
www.reuters.com - May 9 at 4:24 PM
Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial ResultsDova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results
finance.yahoo.com - May 9 at 4:24 PM
Dova Pharmaceuticals (DOVA) Upgraded by ValuEngine to HoldDova Pharmaceuticals (DOVA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 3 at 10:55 PM
Dova Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 9, 2018Dova Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - May 3 at 9:27 AM
Dova Pharmaceuticals (DOVA) Cut to "Sell" at Zacks Investment ResearchDova Pharmaceuticals (DOVA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 27 at 9:16 PM
Dova Pharmaceuticals (DOVA) Earns Buy Rating from Analysts at Ladenburg ThalmannDova Pharmaceuticals (DOVA) Earns Buy Rating from Analysts at Ladenburg Thalmann
www.americanbankingnews.com - April 26 at 9:48 AM
 Analysts Anticipate Dova Pharmaceuticals (DOVA) to Announce -$0.46 Earnings Per Share Analysts Anticipate Dova Pharmaceuticals (DOVA) to Announce -$0.46 Earnings Per Share
www.americanbankingnews.com - April 25 at 7:18 PM
BRIEF-Dova Pharmaceuticals Says On April 17, Co, Unit And SVB Entered Loan And Security AgreementBRIEF-Dova Pharmaceuticals Says On April 17, Co, Unit And SVB Entered Loan And Security Agreement
www.reuters.com - April 20 at 9:47 AM
Dova Pharmaceuticals Inc (DOVA) Given Consensus Rating of "Hold" by AnalystsDova Pharmaceuticals Inc (DOVA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 17 at 1:32 AM
Dova Pharmaceuticals (DOVA) Coverage Initiated by Analysts at Jefferies GroupDova Pharmaceuticals (DOVA) Coverage Initiated by Analysts at Jefferies Group
www.americanbankingnews.com - April 16 at 10:54 PM
Zacks: Brokerages Expect Dova Pharmaceuticals Inc (DOVA) Will Post Earnings of -$0.46 Per ShareZacks: Brokerages Expect Dova Pharmaceuticals Inc (DOVA) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - April 8 at 7:10 PM
Dova Pharmaceuticals (DOVA) Lowered to "Sell" at BidaskClubDova Pharmaceuticals (DOVA) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - March 29 at 11:29 AM
What You Must Know About Dova Pharmaceuticals Inc’s (NASDAQ:DOVA) Financial StrengthWhat You Must Know About Dova Pharmaceuticals Inc’s (NASDAQ:DOVA) Financial Strength
finance.yahoo.com - March 28 at 4:19 PM
Dova Pharmaceuticals (DOVA) Rating Lowered to Sell at BidaskClubDova Pharmaceuticals (DOVA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:10 PM
Dova Pharmaceuticals (DOVA) Upgraded by BidaskClub to HoldDova Pharmaceuticals (DOVA) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - March 23 at 8:28 PM
Dova Pharmaceuticals Inc (DOVA) Given Consensus Recommendation of "Buy" by BrokeragesDova Pharmaceuticals Inc (DOVA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 23 at 11:12 AM
Dova Pharmaceuticals (DOVA) Now Covered by Evercore ISIDova Pharmaceuticals (DOVA) Now Covered by Evercore ISI
www.americanbankingnews.com - March 23 at 10:50 AM
-$0.46 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter-$0.46 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter
www.americanbankingnews.com - March 22 at 7:10 PM
When Can We Expect A Profit From Dova Pharmaceuticals Inc (NASDAQ:DOVA)?When Can We Expect A Profit From Dova Pharmaceuticals Inc (NASDAQ:DOVA)?
finance.yahoo.com - March 20 at 4:14 PM
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong KongDova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong
globenewswire.com - March 20 at 9:48 AM
Dova Pharmaceuticals to Present at Cowen 38th Annual Health Care ConferenceDova Pharmaceuticals to Present at Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 16 at 9:56 AM
 Dova Pharmaceuticals Inc (DOVA) Receives Consensus Recommendation of "Strong Buy" from Analysts Dova Pharmaceuticals Inc (DOVA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 8 at 3:28 AM
Dova Pharmaceuticals (DOVA) vs. Halozyme Therapeutics (HALO) Financial ReviewDova Pharmaceuticals (DOVA) vs. Halozyme Therapeutics (HALO) Financial Review
www.americanbankingnews.com - March 3 at 9:12 PM
Zacks: Dova Pharmaceuticals Inc (DOVA) Given Consensus Recommendation of "Strong Buy" by AnalystsZacks: Dova Pharmaceuticals Inc (DOVA) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - March 3 at 5:28 AM
BidaskClub Lowers Dova Pharmaceuticals (DOVA) to HoldBidaskClub Lowers Dova Pharmaceuticals (DOVA) to Hold
www.americanbankingnews.com - February 24 at 1:28 PM
Dova Pharmaceuticals (DOVA) Commences 2.5M Share Offering of Common StockDova Pharmaceuticals (DOVA) Commences 2.5M Share Offering of Common Stock
www.streetinsider.com - February 21 at 4:35 PM
BRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln SharesBRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln Shares
www.reuters.com - February 21 at 4:35 PM
Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common StockDova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock
finance.yahoo.com - February 20 at 4:45 PM
Research Analysts Set Expectations for Dova Pharmaceuticals Incs FY2021 Earnings (DOVA)Research Analysts Set Expectations for Dova Pharmaceuticals Inc's FY2021 Earnings (DOVA)
www.americanbankingnews.com - February 19 at 9:22 AM
FY2022 Earnings Forecast for Dova Pharmaceuticals Inc Issued By Jefferies Group (DOVA)FY2022 Earnings Forecast for Dova Pharmaceuticals Inc Issued By Jefferies Group (DOVA)
www.americanbankingnews.com - February 19 at 9:18 AM
Dova Pharmaceuticals (DOVA) Upgraded by BidaskClub to BuyDova Pharmaceuticals (DOVA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - February 17 at 2:42 PM
-$0.47 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter-$0.47 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter
www.americanbankingnews.com - February 16 at 11:08 PM

SEC Filings

Dova Pharmaceuticals (NASDAQ:DOVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dova Pharmaceuticals (NASDAQ:DOVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dova Pharmaceuticals (NASDAQ DOVA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.